In Vivo Metabolism & Ocular Tissue Distribution Studies
Generate critical insights into how your drug is metabolized and distributed—including our unmatched expertise in ocular tissues.
Why In Vivo Metabolism & Tissue Distribution Matter
Understanding how a compound is metabolized and distributed in vivo is critical for predicting safety, efficacy, and potential risks in humans—and for ensuring that nonclinical species generate the human-specific metabolite. In vivo metabolism studies uncover species-specific pathways, human-relevant metabolites, and drug–drug interaction potential, while tissue distribution studies provide insights into clearance and target exposure.
In ophthalmology, ocular tissue distribution is especially important. Because key ocular tissues cannot be directly sampled in humans, well-designed preclinical studies are essential for modeling human exposure and informing regulatory submissions. Xyzagen brings deep expertise in ophthalmology drug development to guide these studies.
In Vivo Drug
Metabolism Studies
Xyzagen’s in vivo metabolism expertise ensures your program advances with robust data to support clinical translation. Our studies provide:
Ocular Tissue Distribution Studies
In ophthalmic drug development, understanding how a compound is distributed in the eye after a topical eye drop, intracameral insert, or intravitreal (IVT) injection is critical. Well-designed ocular tissue distribution studies provide insight into clearance and target tissue exposure, and can be used to model and scale data to predict human exposure in tissues that cannot be directly sampled—informing dose selection and regulatory submissions.
Xyzagen’s in vivo ocular tissue distribution expertise ensures your program advances with robust data to support translation into the clinic. With decades of ocular pharmacology and PK expertise, our team supports:
Study Design & Execution
From rodent studies in-house to large animal partnerships, including dosing, bioanalysis, and PK.
Species-to-Human Scaling
Translating ocular distribution data to predict human exposure.
Integration with Clinical Models
Linking nonclinical exposure to clinical trial safety and efficacy through population PK modeling.
The Xyzagen Advantage
At Xyzagen, we don’t just generate numbers—we deliver strategically meaningful data. Our integrated team of PK, TK, bioanalytical experts, and pharmacometricians ensures your studies are designed to answer the right questions and accelerate your program.
Whether you need systemic metabolism insight or ocular distribution expertise, we connect findings to downstream decisions and regulatory expectations.
Partner with Xyzagen
Ready to advance your program with in vivo metabolism or tissue distribution expertise?
Contact us today to design a study that supports translation and regulatory success.
